SightfileU.S. market data from official filings
Companies › CLYM
CLIMB BIO INC (CLYM)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001768446 · EDGAR filings · Updated 2026-07-08
CLIMB BIO INC (CLYM) has reported institutional ownership of 56.4%, with 80 institutional managers holding positions valued at $221.2M per the latest 13F reporting period.
Institutional ownership
56.4%
Institutional managers
80
Reported 13F value
$221.2M
Insider activity
14 trans.
−$126.0K net selling
Latest updates
- 2026-07-08 — SCHEDULE 13G filed
- 2026-07-07 — SCHEDULE 13D/A filed
- 2026-07-01 — Insider transaction reported (Form 4)
- 2026-07-01 — Insider transaction reported (Form 4)
- 2026-07-01 — Initial insider ownership filed (Form 3)
- 2026-07-01 — Current report (8-K) filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, CLIMB BIO INC has 80 institutional holders and institutional ownership of 56.4%.
Insider activity
Insiders reported 14 transactions (3 buys, 6 sells) across 5 reporting insiders, with a net reported value of −$126.0K.
Related companies
CABALETTA BIO INC (CABA) · SINOVAC BIOTECH LTD (SVA) · C4 THERAPEUTICS INC (CCCC) · ALTIMMUNE INC (ALT) · CANDEL THERAPEUTICS INC (CADL) · FOGHORN THERAPEUTICS INC (FHTX)
See full history, cross-references and alerts on SightfileSightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-08.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-08.